Abstract
In 2006, MD Anderson group published a new classification of pancreatic ductal adenocarcinoma (PDAC) that took into account the degree of neoplastic involvement of peripancreatic vessels.[1] According to that, PDAC was classified as resectable, borderline resectable (BR), or locally advanced (LA).[1] From its introduction, this classification has been universally adopted, allowing a standardization of terminology used by different pancreatic centers. If, in case of resectable PDAC, upfront radical surgery followed by adjuvant chemotherapy is the gold standard treatment,[2] on the other hand, the optimal treatment strategy of patients with BR and LA-PDAC is complex, and it is still matter of debate.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
